Seeking Alpha


Send Message
View as an RSS Feed
View mowadeeb1's Comments BY TICKER:
Latest  |  Highest rated
  • Ed Quilty, CEO Of Derma Sciences, Outlines His Strategy To Build A Premier Wound Healing Company [View article]
    I think that you give Quilty too much praise. First of all, he bankrupted the company once already and then initiated a reverse split. The first time they raised cash through a stock sale, they said it was to develop DSC 127 with a partner, and that partnership negotiations were taking place. Then they turn around and raise money again by selling stock and said this is the last time they will need to raise cash. Then they buy a company which they have no business buying and need to raise cash again saying now that they are going to go it alone on DSC 127. Quilty has no experience and no business running a phase III trial. He should have signed a lucrative deal with a experienced partner to run the trial. Also, instead of constantly raising cash he should sell off the low margin wound care part of the business. I think that Quilty is in way over his head.
    May 4, 2014. 10:13 AM | Likes Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Steve, I have heard no mention of Reduce - it interim results to be released in this quarter. I think you are confusing this with the statin combo results which the company stated would be released before middle of the year. This is very early data and will probably not have much of an effect on share price.
    Apr 25, 2013. 04:39 PM | Likes Like |Link to Comment
  • New FDA Document Could Mean NCE For Amarin [View instapost]
    Thanks Steve!! AF is already tweeting about it saying that the FDA guidelines makes it very easy for a generic version to come to market. He says that they will have to rely on patents to defend.
    Apr 9, 2013. 07:36 PM | Likes Like |Link to Comment
  • Amarin Announces Additional Data From Clinical Trials [View instapost]
    Steve, JPM out with a note today saying they do not see a buy out this year. Are you still firm in your belief of a buy out "near term"? The action in this stock is just horrible and screams a vote of no confidence in management.
    Apr 8, 2013. 10:21 PM | Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    The issue of value seems like it could be solved by using a CVR in a buy out. For example, $25.00 cash plus a CVR consisting of the following milestones.

    1. The receipt of NCE designation $5.00 per share

    2. The approval of the Anchor indication $10.00 per share

    3. Additional pay outs based on sales milestones over a several year period.

    This is a crude illustration however it allows both parties to assume some risk and to reap the rewards. It hands the asset over to BP right away and lets them run with it. I have seen CVR'S with some crazy structures and many many milestones built into them with nice payments for these milestones being met. This seems like an elegant way to solve the valuation gap.
    Dec 15, 2012. 04:19 AM | 1 Like Like |Link to Comment
  • The Latest On Amarin - How Will The Investment Pay Off? [View article]

    Thank you very much for sharing your thoughts on amrn. I have been a shareholder since the low single digit days. It has been a long strange trip to say the least. I am firmly in the buy out camp as I see this as the best ending to a great story. The problem I see is that it would be difficult to get a price where I think it would need to be with the share price so depressed. If we get a positive nce decision, we should get a pop to around 15 or so. Even at that price it is still very difficult to see a BP going all the way up to 35+. So here is my question. Do you see the possibility of something like a 25-30 per share offer with a very lucrative CVR attached? I would love to see this type of structured deal as I believe that there would be alot of upside to a well thought out CVR. Thank you once again for all of your efforts!!!
    Nov 27, 2012. 02:04 AM | Likes Like |Link to Comment
1 Like